SCHEMBL7555346

SCHEMBL7555346

CCN1CCN=C1CC(c1cccc(OC)c1)c1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.45
DRD2 P14416 3/20 0.43
ALDH1A1 P00352 3/20 0.39
KCNA5 P22460 1/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
OPRM1 P35372 1/20 0.37
DRD3 P35462 1/20 0.37
CHRM2 P08172 1/20 0.36
SCN1A P35498 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PKM P14618 1/20 0.36
KDM2B Q8NHM5 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7549134 0.92 DRD4 (0.48) DRD4DRD2ALDH1A1KCNA5SLC6A2
SCHEMBL7550921 0.88 DRD2 (0.46) DRD4DRD2ALDH1A1SLC6A2SLC6A4
SCHEMBL7548092 0.83 DRD2 (0.47) DRD4DRD2ALDH1A1MTNR1AMTNR1B
SCHEMBL7552597 0.82 DRD2 (0.46) DRD4DRD2ALDH1A1SMN1; SMN2KDM2B
SCHEMBL7552605 0.80 DRD2 (0.40) DRD4DRD2ALDH1A1SLC6A2SLC6A4
SCHEMBL7549185 0.77 NISCH (0.53) DRD2SLC6A2SLC6A4CHRM2SCN1A
SCHEMBL7551253 0.76 DRD2 (0.41) DRD2KCNA5SLC6A2SLC6A4CHRM2
SCHEMBL7554011 0.75 NISCH (0.45) DRD2ALDH1A1SLC6A2SLC6A4CHRM2
SCHEMBL7546358 0.73 PBRM1 (0.46) DRD2KCNA5SLC6A2SLC6A4CHRM2
SCHEMBL7547015 0.72 DRD2 (0.41) DRD2ALDH1A1KCNA5SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US disclosed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132812-A1 Oral hypoglycaemic agents SLC5A2, GPR119, SLC5A1 DRD4 2942/4885DRD2 3857/4885ALDH1A1 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.